Edwards Follows Guidant’s Exit From AAA Market, Seeks Lifepath Acquirer
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences' decision to suspend its Lifepath endovascular graft program accompanies a realignment of R&D priorities to cope with the rapidly maturing AAA market